PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32250214-7 2020 Parthenolide, apocynin, proanthocyanidins and boswellic acid present different mechanisms of actions - among others, through NF-kappaB or NADPH oxidase inhibition, therefore showing a wide range of applications in various inflammatory diseases. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 125-134 34575860-12 2021 Pharmacological inhibition of NF-kappaB by parthenolide diminished CsA- and Tac-mediated proinflammatory effects. parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 30-39 34405014-0 2021 Suppression Of Aberrant Activation Of NF-kappaB Pathway In Drug-resistant Leukemia Stem Cells Contributes To Parthenolide-potentiated Reversal Of Drug Resistance In Leukemia. parthenolide 109-121 nuclear factor kappa B subunit 1 Homo sapiens 38-47 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 6-18 nuclear factor kappa B subunit 1 Homo sapiens 46-55 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 6-18 nuclear factor kappa B subunit 1 Homo sapiens 209-218 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 20-23 nuclear factor kappa B subunit 1 Homo sapiens 46-55 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. parthenolide 20-23 nuclear factor kappa B subunit 1 Homo sapiens 209-218 33258341-5 2020 Mechanistically, PTL treatment resulted in downregulation of NF-kappaB activity and Bcl-2 expression, and upregulation of Caspase-8 activity. parthenolide 17-20 nuclear factor kappa B subunit 1 Homo sapiens 61-70 32887995-11 2020 The drugs parthenolide and dimethyl fumarate have both been shown to effectively inhibit NFkappaB, reducing tumor aggressiveness and reversing endocrine therapy resistance. parthenolide 10-22 nuclear factor kappa B subunit 1 Homo sapiens 89-97 32823992-2 2020 Parthenolide (PN) has been shown to inhibit NF-kappaB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in several cancers. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 44-53 32823992-2 2020 Parthenolide (PN) has been shown to inhibit NF-kappaB signaling and other pro-survival signaling pathways, induce apoptosis and reduce a subpopulation of cancer stem-like cells in several cancers. parthenolide 14-16 nuclear factor kappa B subunit 1 Homo sapiens 44-53 32751648-3 2020 Parthenolide (PTL) is an abundant sesquiterpene lactone, found in Mexican Indian Asteraceae family plants, with reported anti-inflammatory activity, through the inhibition of a common step in the NF-kappaB activation pathway. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 196-205 32751648-3 2020 Parthenolide (PTL) is an abundant sesquiterpene lactone, found in Mexican Indian Asteraceae family plants, with reported anti-inflammatory activity, through the inhibition of a common step in the NF-kappaB activation pathway. parthenolide 14-17 nuclear factor kappa B subunit 1 Homo sapiens 196-205 31164821-0 2019 Collateral Sensitivity of Parthenolide via NF-kappaB and HIF-alpha Inhibition and Epigenetic Changes in Drug-Resistant Cancer Cell Lines. parthenolide 26-38 nuclear factor kappa B subunit 1 Homo sapiens 43-52 31608008-7 2019 Similar results were observed in human tubular cells (HK-2) subjected to high-glucose (HG) conditions and treated with TAK-242 or parthenolide (inhibitor of NF-kappaB) by Western blot, Enzyme-linked immunosorbent assay (ELISA), and flow cytometry. parthenolide 130-142 nuclear factor kappa B subunit 1 Homo sapiens 157-166 28782644-2 2017 Our lab and others have demonstrated that the natural product parthenolide can inhibit NF-kappaB activity and sensitize PC-3 prostate cancers cells to X-rays in vitro; however, parthenolide has poor bioavailability in vivo and therefore has little clinical utility in this regard. parthenolide 62-74 nuclear factor kappa B subunit 1 Homo sapiens 87-96 30079458-5 2018 PTL and DMAPT caused an increase in reactive oxygen species (ROS) levels and inhibited NF-kappaB activation. parthenolide 0-3 nuclear factor kappa B subunit 1 Homo sapiens 87-96 29705182-7 2018 Genetic or pharmacological (especially parthenolide) inhibition of NF-kappaB activity down-regulated MGMT gene expression and substantially restored TMZ chemosensitivity in vitro and in vivo. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 67-76 28965856-3 2017 Here, we report that pretreatment of osteoblasts with the sesquiterpene lactone Parthenolide (PTN), a verified NFkappaB inhibitor, prior to exposure to conditioned medium from human and mouse breast cancer cell lines enhanced osteoblast differentiation and reduced osteoblast ability to stimulate osteoclastogenesis. parthenolide 80-92 nuclear factor kappa B subunit 1 Homo sapiens 111-119 28965856-3 2017 Here, we report that pretreatment of osteoblasts with the sesquiterpene lactone Parthenolide (PTN), a verified NFkappaB inhibitor, prior to exposure to conditioned medium from human and mouse breast cancer cell lines enhanced osteoblast differentiation and reduced osteoblast ability to stimulate osteoclastogenesis. parthenolide 94-97 nuclear factor kappa B subunit 1 Homo sapiens 111-119 28782644-3 2017 We show here that treatment of PC-3 and DU145 human prostate cancer cells with dimethylaminoparthenolide (DMAPT), a parthenolide derivative with increased bioavailability, inhibits constitutive and radiation-induced NF-kappaB binding activity and slows prostate cancer cell growth. parthenolide 92-104 nuclear factor kappa B subunit 1 Homo sapiens 216-225 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 163-185 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 187-196 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 100-103 nuclear factor kappa B subunit 1 Homo sapiens 163-185 28829282-4 2017 We have previously shown the anti-inflammatory and antiosteoclastogenic activities of parthenolide (PTL) in human periodontal ligament-derived cells by inhibiting nuclear factor kappa B (NF-kappaB) signaling, indicating its potential for periodontitis treatment. parthenolide 100-103 nuclear factor kappa B subunit 1 Homo sapiens 187-196 28829282-7 2017 In addition, PTL inhibited the NF-kappaB/p50 pathway and resisted the inhibition of Wnt/beta-catenin signaling induced by TNF-alpha. parthenolide 13-16 nuclear factor kappa B subunit 1 Homo sapiens 31-40 28829282-7 2017 In addition, PTL inhibited the NF-kappaB/p50 pathway and resisted the inhibition of Wnt/beta-catenin signaling induced by TNF-alpha. parthenolide 13-16 nuclear factor kappa B subunit 1 Homo sapiens 41-44 29050271-4 2017 We showed that PTL inhibited the proliferation and migration by reverse EMT via the ERK2/NF-kappaB/Snail pathway in vivo and in vitro. parthenolide 15-18 nuclear factor kappa B subunit 1 Homo sapiens 89-98 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 40-62 28108625-0 2017 Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-kappaB Activation. parthenolide 9-21 nuclear factor kappa B subunit 1 Homo sapiens 91-100 28108625-2 2017 Parthenolide, a strong NF-kappaB inhibitor, has recently been demonstrated to be a promising therapeutic agent, promoting apoptosis of cancer cells. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 23-32 28108625-4 2017 The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets. parthenolide 64-76 nuclear factor kappa B subunit 1 Homo sapiens 135-144 28108625-4 2017 The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets. parthenolide 64-76 nuclear factor kappa B subunit 1 Homo sapiens 177-186 28108625-4 2017 The results demonstrate that the combination of balsalazide and parthenolide markedly suppress proliferation, nuclear translocation of NF-kappaB, IkappaB-alpha phosphorylation, NF-kappaB DNA binding, and expression of NF-kappaB targets. parthenolide 64-76 nuclear factor kappa B subunit 1 Homo sapiens 177-186 28108625-8 2017 These results demonstrate that parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-kappaB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation. parthenolide 31-43 nuclear factor kappa B subunit 1 Homo sapiens 118-127 27757770-6 2016 Further, LPS-stimulated phosphorylation of NF-kappaB, the key regulatory transcription factor in ALI, was inhibited by parthenolide treatment in lung epithelial BEAS-2B cells and alveolar macrophage MH-S cells. parthenolide 119-131 nuclear factor kappa B subunit 1 Homo sapiens 43-52 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 64-72 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 138-150 nuclear factor kappa B subunit 1 Homo sapiens 40-49 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 138-150 nuclear factor kappa B subunit 1 Homo sapiens 118-127 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 152-154 nuclear factor kappa B subunit 1 Homo sapiens 40-49 26821066-6 2016 CJ also provoked a slight activation of NF-kappaB, and consistent with this notion a combined treatment of CJ and the NF-kappaB inhibitor parthenolide (Pt) led to a remarkable synergistic cell death in T-ALL cells. parthenolide 152-154 nuclear factor kappa B subunit 1 Homo sapiens 118-127 26821066-7 2016 Altogether, our data support the concept that inhibition of the SERCA pump may be a novel strategy for the treatment of T-ALL with HD-domain-mutant Notch1 receptors and that additional treatment with the NF-kappaB inhibitor parthenolide may have further therapeutic benefits. parthenolide 224-236 nuclear factor kappa B subunit 1 Homo sapiens 204-213 25971793-3 2015 However, the effect of parthenolide on the Akt/mTOR and NF-kappaB pathway activation-induced productions of inflammatory mediators in keratinocytes has not been studied. parthenolide 23-35 nuclear factor kappa B subunit 1 Homo sapiens 56-65 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 79-87 26206887-7 2015 Notch siRNA prevented the activation of nuclear factor kappa B (NFkappaB), and NFkappaB activation contributed to Notch1-mediated inflammatory responses as the NFkappaB inhibitor, parthenolide, prevented lyso-Gb3-induced chemokine upregulation. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 79-87 25971793-0 2015 Sesquiterpene lactone parthenolide attenuates production of inflammatory mediators by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 165-174 25971793-4 2015 Using human keratinocytes, we investigated the effect of parthenolide on the inflammatory mediator production in relation to the Toll-like receptor-4-mediated-Akt/mTOR and NF-kappaB pathways, which regulate the transcription genes involved in immune and inflammatory responses. parthenolide 57-69 nuclear factor kappa B subunit 1 Homo sapiens 172-181 25971793-6 2015 The results show that parthenolide appears to attenuate the lipopolysaccharide-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor-4-mediated activation of the Akt, mTOR, and NF-kappaB pathways. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 226-235 26160345-4 2015 Application of different inhibitors and activators showed that transcription factors NF-kappaB (inhibitors caffeic acid phenethyl ester and parthenolide, activator betulinic acid), AP-1 (inhibitor SR11302), and STAT-3 (inhibitors stattic and cucurbitacine) influenced PDT-induced death and survival of neurons and glial cells in different ways. parthenolide 140-152 nuclear factor kappa B subunit 1 Homo sapiens 85-94 24080940-2 2013 Susceptibility to eryptosis is enhanced in aged erythrocytes and stimulated by NFkappaB-inhibitors Bay 11-7082 and parthenolide. parthenolide 115-127 nuclear factor kappa B subunit 1 Homo sapiens 79-87 26072071-0 2015 Inhibitory effects of parthenolide on the activity of NF-kappaB in multiple myeloma via targeting TRAF6. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 54-63 26072071-1 2015 This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-kappaB in multiple myeloma (MM). parthenolide 62-74 nuclear factor kappa B subunit 1 Homo sapiens 100-109 26072071-1 2015 This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-kappaB in multiple myeloma (MM). parthenolide 76-79 nuclear factor kappa B subunit 1 Homo sapiens 100-109 26072071-7 2015 Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IkappaB-alpha and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-kappaB. parthenolide 31-34 nuclear factor kappa B subunit 1 Homo sapiens 213-222 26072071-11 2015 Taken together, our findings suggest that PTL inhibits the activation of NF-kappaB signaling pathway via directly binding with TRAF6, thereby suppressing MM cell proliferation and inducing apoptosis. parthenolide 42-45 nuclear factor kappa B subunit 1 Homo sapiens 73-82 25553117-0 2015 Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-kappaB/COX-2 pathway. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 112-121 25553117-8 2015 In addition, parthenolide exhibited an inhibitory effect on nuclear factor-kappa B (NF-kappaB) nucler translocation by suppressing both the phosphorylation of IkappaB kinase complex and IkappaBalpha degradation. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 60-82 25553117-8 2015 In addition, parthenolide exhibited an inhibitory effect on nuclear factor-kappa B (NF-kappaB) nucler translocation by suppressing both the phosphorylation of IkappaB kinase complex and IkappaBalpha degradation. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 84-93 25553117-9 2015 Taken together, these results suggest that parthenolide may exert its cancer stem cell-targeted chemotherapy through the NF-kappaB/COX-2 pathway. parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 121-130 23792430-0 2013 Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-kappaB activation and HSP70 up-regulation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 95-104 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 71-80 23898080-9 2013 Parthenolide markedly reduced the constitutive and doxorubicin-induced NF-kappaB activity measured as the nuclear NF-kappaB, and expression of matrix metalloproteinase-9 (MMP9) and it had no effect on p53. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 114-123 25611383-2 2015 We recently developed dimethylaminoparthenolide (DMAPT), a clinical grade water-soluble analog of parthenolide, as a potent inhibitor of NF-kappaB and demonstrated in vitro and in vivo anti-tumor activities in multiple cancers. parthenolide 35-47 nuclear factor kappa B subunit 1 Homo sapiens 137-146 25611383-9 2015 These results add KMT5C to the list NF-kappaB-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. parthenolide 80-92 nuclear factor kappa B subunit 1 Homo sapiens 36-45 27122844-2 2015 Parthenolide, a sesquiterpene lactone compound which could inhibit NF-kappa B, has been shown to ameliorate myocardial reperfusion injury but may also produce toxic effects in cardiomyocytes at high concentrations. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 67-77 23999007-12 2013 TWEAK activated NFkappaB and increased MCP-1 mRNA and protein, an effect prevented by the NFkappaB inhibitor parthenolide. parthenolide 109-121 nuclear factor kappa B subunit 1 Homo sapiens 16-24 23999007-12 2013 TWEAK activated NFkappaB and increased MCP-1 mRNA and protein, an effect prevented by the NFkappaB inhibitor parthenolide. parthenolide 109-121 nuclear factor kappa B subunit 1 Homo sapiens 90-98 23575899-3 2013 The results showed that the apoptosis of porcine granulosa cells induced by CdCl2 significantly increased in a time- and dose-dependent manner along with the increasing of ROS production, and 10 muM parthenolide, an inhibitor NF-kappaB, can accelerate the process of apoptosis. parthenolide 199-211 nuclear factor kappa B subunit 1 Homo sapiens 226-235 24080940-10 2013 CONCLUSION: NFkappaB protein abundance is lowest and spontaneous eryptosis as well as susceptibility to Bay 11-7082 and parthenolide highest in aged erythrocytes. parthenolide 120-132 nuclear factor kappa B subunit 1 Homo sapiens 12-20 23039130-0 2012 Involvement of Akt/NF-kappaB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. parthenolide 61-73 nuclear factor kappa B subunit 1 Homo sapiens 19-28 23039130-4 2012 Our study aimed to evaluate the antitumour effects of parthenolide, a NF-kappaB inhibitor, in two human glioblastoma cell lines (U87MG and U373) and in glioblastoma xenografts. parthenolide 54-66 nuclear factor kappa B subunit 1 Homo sapiens 70-79 23383347-8 2013 Using immunofluorescence staining assay, the EGF-stimulated nuclear translocation of NF-kappaB (p65) was inhibited by pre-treating cells with LY294002 and parthenolide. parthenolide 155-167 nuclear factor kappa B subunit 1 Homo sapiens 85-94 22238372-6 2012 Pretreatment of trophoblasts with selective inhibitors of I-kB kinase activity (parthenolide and TPCA-1) reduced oxysterol- and LPS-stimulated inflammatory responses, consistent with the involvement of the nuclear factor kappa B (NF-kappaB) pathway downstream of TLR4 signalling. parthenolide 80-92 nuclear factor kappa B subunit 1 Homo sapiens 230-239 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 nuclear factor kappa B subunit 1 Homo sapiens 27-36 22683888-8 2012 Consistent with a role for NF-kappaB in the changes caused by TNF-alpha, treatment with the NF-kappaB inhibitor parthenolide restored PPAR DNA-binding activity, the expression of PPARbeta/delta-target genes and the expression of SIRT1 and PPARbeta/delta. parthenolide 112-124 nuclear factor kappa B subunit 1 Homo sapiens 92-101 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 196-205 23039130-11 2012 Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling, suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-kappaB but also by the inhibition of Akt signalling and the activation of apoptotic proteins. parthenolide 137-149 nuclear factor kappa B subunit 1 Homo sapiens 196-205 22155272-2 2012 We show that parthenolide inhibited NF-kappaB transcription factor c-Rel (REL). parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 36-45 21289336-0 2011 Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 17-26 22105338-9 2012 In conclusion, the pharmacological inhibitors of the NFkappaB pathway Bay 11-7082 and parthenolide interfere with the survival of erythrocytes involving mechanisms other than disruption of NFkappaB-dependent gene expression. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 53-61 21992677-14 2011 Parthenolide inhibited both NFkappaB and MAPK/AP-1 pathways contributing to the inhibition of IL-8 production. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 28-36 20870895-13 2011 The NF-kappaB inhibitors gliotoxin and parthenolide increased apoptosis and decreased IL-8 and CXCR2 expression. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 4-13 21289336-7 2011 The phosphorylation of NF-kappaB was down-regulated by the treatment of parthenolide. parthenolide 72-84 nuclear factor kappa B subunit 1 Homo sapiens 23-32 21289336-1 2011 AIM: This study evaluated the sesquiterpene lactone parthenolide, an inhibitor of transcription factor nuclear factor-kappaB (NF-kappaB), in the treatment of gastric cancer in vitro and in vivo. parthenolide 52-64 nuclear factor kappa B subunit 1 Homo sapiens 103-124 21289336-11 2011 CONCLUSION: The NF-kappaB inhibitor, parthenolide, may enhance chemosensitivity to paclitaxel in the treatment of patients with gastric cancer. parthenolide 37-49 nuclear factor kappa B subunit 1 Homo sapiens 16-25 21289336-1 2011 AIM: This study evaluated the sesquiterpene lactone parthenolide, an inhibitor of transcription factor nuclear factor-kappaB (NF-kappaB), in the treatment of gastric cancer in vitro and in vivo. parthenolide 52-64 nuclear factor kappa B subunit 1 Homo sapiens 126-135 20701602-1 2010 Interactions between the nuclear factor (NF)-kappaB inhibitor parthenolide and the pan-histone deacetylase inhibitors (HDACIs) vorinostat and LBH589 were investigated in human acute myeloid leukaemia (AML) cells, including primary AML blasts. parthenolide 62-74 nuclear factor kappa B subunit 1 Homo sapiens 25-51 21325821-2 2011 The substances interfere with the activation and nuclear translocation of nuclear factor NFkappaB, by inhibiting NFkappaB directly (parthenolide) or by interfering with the inactivation of the NFkappaB inhibitory protein IkappaB-alpha (Bay 11-7082). parthenolide 132-144 nuclear factor kappa B subunit 1 Homo sapiens 89-97 21325821-2 2011 The substances interfere with the activation and nuclear translocation of nuclear factor NFkappaB, by inhibiting NFkappaB directly (parthenolide) or by interfering with the inactivation of the NFkappaB inhibitory protein IkappaB-alpha (Bay 11-7082). parthenolide 132-144 nuclear factor kappa B subunit 1 Homo sapiens 113-121 21325821-2 2011 The substances interfere with the activation and nuclear translocation of nuclear factor NFkappaB, by inhibiting NFkappaB directly (parthenolide) or by interfering with the inactivation of the NFkappaB inhibitory protein IkappaB-alpha (Bay 11-7082). parthenolide 132-144 nuclear factor kappa B subunit 1 Homo sapiens 113-121 21325821-8 2011 Targeting the NFkappaB pathway by Bay 11-7082 (IC(50) 10 muM) and parthenolide (IC(50) 30 muM) triggered suicidal erythrocyte death as shown by annexin V binding and decrease of forward scatter. parthenolide 68-80 nuclear factor kappa B subunit 1 Homo sapiens 14-22 21325821-11 2011 In conclusion, the pharmacological inhibitors of NFkappaB, Bay 11-7082 and parthenolide, interfere with the survival of erythrocytes involving mechanisms other than disruption of NFkappaB-dependent gene expression. parthenolide 75-87 nuclear factor kappa B subunit 1 Homo sapiens 49-57 21625432-4 2011 However, addition of the NF-kappaB inhibitor parthenolide to these cells prevents the downregulation of PDK4 expression but not ERRalpha and PPARbeta/delta DNA binding activity, thus suggesting that additional transcription factors are regulating PDK4. parthenolide 45-57 nuclear factor kappa B subunit 1 Homo sapiens 25-34 21625432-9 2011 Interestingly, the NF-kappaB inhibitor parthenolide prevented the inhibition of E2F1, while E2F1 overexpression reduced interleukin expression in stimulated cardiac cells. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 19-28 20718930-7 2010 However, inhibition of IkappaB (IKK) kinase by parthenolide by stopping NF-kappaB release from the complex with IkappaB did not prevent onset of resistance, but it invoked some resistance even in groups with shorter, 1 h dark pause. parthenolide 47-59 nuclear factor kappa B subunit 1 Homo sapiens 72-81 20702415-6 2010 Interestingly, the recruitment of both MTA1 and MyD88 expression is effectively blocked by NF-kappaB inhibitor parthenolide. parthenolide 111-123 nuclear factor kappa B subunit 1 Homo sapiens 91-100 20434582-4 2010 Thus, secretion of IL-1beta decreased significantly when cells were depleted of NLRP3 or treated with the anti-inflammatory inhibitors parthenolide or Bay 11-7082, which inhibit inflammasomes and the transcription factor NF-kappaB. parthenolide 135-147 nuclear factor kappa B subunit 1 Homo sapiens 221-230 20209491-0 2010 A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. parthenolide 16-28 nuclear factor kappa B subunit 1 Homo sapiens 93-101 20590608-7 2010 KEY RESULTS: Parthenolide suppressed both constitutive and induced NF-kappaB activity in melanoma cells. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 67-76 20590608-10 2010 These findings not only reflected differences between melanoma cell lines in basal expression of NF-kappaB-regulated genes, but also suggested other parthenolide targets involved in cell cycle progression, migration, invasiveness and survival. parthenolide 149-161 nuclear factor kappa B subunit 1 Homo sapiens 97-106 20590608-11 2010 CONCLUSIONS: Inhibition of constitutive and therapeutically induced NF-kappaB pathway by parthenolide might be useful in the treatment of melanoma, although the diversity of changes induced in melanoma cells with different genetic backgrounds indicate context-dependent poly-pharmacological properties of this compound. parthenolide 89-101 nuclear factor kappa B subunit 1 Homo sapiens 68-77 20582811-5 2010 The natural products curcumin, resveratrol and parthenolide are known inhibitors of the activation of NF-kappaB. parthenolide 47-59 nuclear factor kappa B subunit 1 Homo sapiens 102-111 20540695-9 2010 We found that either parthenolide or magnolol could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 21-33 nuclear factor kappa B subunit 1 Homo sapiens 104-113 20540695-9 2010 We found that either parthenolide or magnolol could effectively inhibit the gene expression mediated by NF-kappaB and the production of bFGF and MMP-1 from cells overexpressing p65, a major subunit of NF-kappaB. parthenolide 21-33 nuclear factor kappa B subunit 1 Homo sapiens 201-210 20224758-8 2009 Parthenolide inhibited both NFkappaB translocation and TNFalpha protein expression indicating that NFkappaB seems to be necessary. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 28-36 19821157-5 2010 Parthenolide was added as NF-kappaB inhibitor. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 26-35 19821157-9 2010 The levels of NF-kappaB and API-5, as well as NF-kappaB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. parthenolide 160-172 nuclear factor kappa B subunit 1 Homo sapiens 14-23 19821157-9 2010 The levels of NF-kappaB and API-5, as well as NF-kappaB activity and API-5 phosphorylation level, were in accordance with Pim-2 level, but could be reversed by Parthenolide. parthenolide 160-172 nuclear factor kappa B subunit 1 Homo sapiens 46-55 20151982-6 2010 Inhibition of HIF-1alpha by chetomin and NF-kappaB by parthenolide reduced mRNA and protein expression of the studied molecules and prevented invasion of hypoxic MCF-7 cells. parthenolide 54-66 nuclear factor kappa B subunit 1 Homo sapiens 41-50 19774508-0 2010 Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 127-136 19774508-3 2010 Thus, this study was performed to explore the effect of parthenolide, a natural NF-kappaB inhibitor, on human lung cancer A549 cells treated with low-dose oxaliplatin, as well as to determine the potential mechanisms involved. parthenolide 56-68 nuclear factor kappa B subunit 1 Homo sapiens 80-89 19943112-6 2010 Interestingly, selective inactivation of NF-kappaB using either an NF-kappaB decoy or parthenolide, a blocker of IKK-dependent NF-kappaB activation, reduced, rather then increased, apoptosis and p53 levels in FC1-depleted cells. parthenolide 86-98 nuclear factor kappa B subunit 1 Homo sapiens 41-50 19956548-8 2009 Together these data support the likelihood that GSH inhibits the effect of parthenolide on JNK, NFkappaB and cell death through its direct inhibition of parthenolide"s modulation of exofacial thiols. parthenolide 75-87 nuclear factor kappa B subunit 1 Homo sapiens 96-104 19584059-6 2009 An inhibition of NF-kappaB activity by parthenolide significantly increased the transcriptional activity of the F-promoter. parthenolide 39-51 nuclear factor kappa B subunit 1 Homo sapiens 17-26 19404004-8 2009 Parthenolide is one of the main sesquiterpense lactones responsible for the bioactivities of feverfew and recently reported to inhibit NFkappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 135-143 19774508-8 2010 These findings indicate that parthenolide could markedly enhance sensitivity of A549 cells to low-dose oxaliplatin by inhibiting NF-kappaB activation and inducing apoptosis. parthenolide 29-41 nuclear factor kappa B subunit 1 Homo sapiens 129-138 19397439-0 2009 Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells. parthenolide 37-49 nuclear factor kappa B subunit 1 Homo sapiens 15-24 19397439-1 2009 We have shown that parthenolide, a sesquiterpene lactone, is a radiation sensitizer for human CGL1 hybrid cells that have constitutively activated NF-kappaB and wild-type p53. parthenolide 19-31 nuclear factor kappa B subunit 1 Homo sapiens 147-156 19397439-6 2009 We hypothesized that inhibition of NF-kappaB activity by parthenolide was responsible for the observed X-ray sensitization and inhibition of split-dose repair. parthenolide 57-69 nuclear factor kappa B subunit 1 Homo sapiens 35-44 19397439-8 2009 Inhibition of NF-kappaB activity by knockdown of p65 increased radiation sensitivity and completely inhibited split-dose repair in both cell lines in a nearly identical manner as parthenolide treatment alone. parthenolide 179-191 nuclear factor kappa B subunit 1 Homo sapiens 14-23 19397439-10 2009 We propose that the suppression of radiation-induced NF-kappaB activity by parthenolide leads to X-ray sensitization through inhibition of split-dose repair in p53 null PC-3 prostate cancer cells. parthenolide 75-87 nuclear factor kappa B subunit 1 Homo sapiens 53-62 20224758-8 2009 Parthenolide inhibited both NFkappaB translocation and TNFalpha protein expression indicating that NFkappaB seems to be necessary. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 99-107 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 60-72 nuclear factor kappa B subunit 1 Homo sapiens 119-140 18652825-7 2008 A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 35-43 18652825-7 2008 A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 135-143 18652825-8 2008 ChIP assay also demonstrated that TSA treatment increased while TSA/parthenolide cotreatment decreased NFkappaB p65 binding to STC1 gene promoter. parthenolide 68-80 nuclear factor kappa B subunit 1 Homo sapiens 103-111 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 60-72 nuclear factor kappa B subunit 1 Homo sapiens 142-151 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 74-77 nuclear factor kappa B subunit 1 Homo sapiens 119-140 18425350-1 2008 The thermo-enhancement effects of the sesquiterpene lactone parthenolide (PTL), which targets the transcription factor nuclear factor-kappaB (NF-kappaB), and hyperthermia at 40, 42 and 44 degrees C on the human lung adenocarcinoma A549 cell line were investigated in vitro. parthenolide 74-77 nuclear factor kappa B subunit 1 Homo sapiens 142-151 18425350-11 2008 Our results suggested that the PTL-induced apoptosis of A549 cells was due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling. parthenolide 31-34 nuclear factor kappa B subunit 1 Homo sapiens 104-113 18425350-11 2008 Our results suggested that the PTL-induced apoptosis of A549 cells was due to the direct suppression of NF-kappaB activity in a p53- and hsp72-independent manner based on NF-kappaB signaling. parthenolide 31-34 nuclear factor kappa B subunit 1 Homo sapiens 171-180 18347184-2 2008 The sesquiterpene lactone parthenolide targets NF-kappaB. parthenolide 26-38 nuclear factor kappa B subunit 1 Homo sapiens 47-56 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 nuclear factor kappa B subunit 1 Homo sapiens 22-31 19023456-7 2008 This anti-apoptotic effect was lost when cells were pretreated with parthenolide, an inhibitor of NFkappaB activation. parthenolide 68-80 nuclear factor kappa B subunit 1 Homo sapiens 98-106 19116667-5 2008 Pretreatment with the NF-kappaB inhibitor parthenolide provided evidence that Tat+/-morphine-induced release of MCP-1, IL-6 and TNF-alpha by astrocytes is NF-kappaB dependent. parthenolide 42-54 nuclear factor kappa B subunit 1 Homo sapiens 155-164 18088190-0 2007 Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 82-91 18088190-3 2007 We investigated whether parthenolide would enhance X-ray-induced cell killing in radiation resistant, NF-kappaB-activated CGL1 cells. parthenolide 24-36 nuclear factor kappa B subunit 1 Homo sapiens 102-111 18088190-4 2007 Treatment with 5 microM parthenolide for 48 to 72 h inhibited constitutive NF-kappaB binding and cell growth, reduced plating efficiency, and induced apoptosis through stabilization of p53 (TP53), induction of the pro-apoptosis protein BAX, and phosphorylation of BID. parthenolide 24-36 nuclear factor kappa B subunit 1 Homo sapiens 75-84 17325184-8 2007 The impact of the NF-kappaB inhibition was assessed by using parthenolide. parthenolide 61-73 nuclear factor kappa B subunit 1 Homo sapiens 18-27 17290398-7 2007 Localization of NF-kappaB in response to parthenolide treatment was examined of by immunofluorostaining of OUR-10 cells with antibody against NF-kappaB p65 and by Western blot analysis of OUR-10 cell and tumor nuclear and cytosol fraction. parthenolide 41-53 nuclear factor kappa B subunit 1 Homo sapiens 16-25 17290398-7 2007 Localization of NF-kappaB in response to parthenolide treatment was examined of by immunofluorostaining of OUR-10 cells with antibody against NF-kappaB p65 and by Western blot analysis of OUR-10 cell and tumor nuclear and cytosol fraction. parthenolide 41-53 nuclear factor kappa B subunit 1 Homo sapiens 142-151 17290398-10 2007 Immunohistochemistry and Western blot analysis showed decreased nuclear localization of NF-kappaB and phosphorylated NF-kappaB protein and subsequently expression of MMP-9, Bcl-xL and Cox-2 in response to parthenolide treatment. parthenolide 205-217 nuclear factor kappa B subunit 1 Homo sapiens 88-97 17290398-10 2007 Immunohistochemistry and Western blot analysis showed decreased nuclear localization of NF-kappaB and phosphorylated NF-kappaB protein and subsequently expression of MMP-9, Bcl-xL and Cox-2 in response to parthenolide treatment. parthenolide 205-217 nuclear factor kappa B subunit 1 Homo sapiens 117-126 17290398-11 2007 These results indicate that parthenolide is a useful in the treatment of renal cell carcinoma and acts via inhibition of NF-kappaB. parthenolide 28-40 nuclear factor kappa B subunit 1 Homo sapiens 121-130 17290398-0 2007 Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. parthenolide 22-34 nuclear factor kappa B subunit 1 Homo sapiens 136-145 17290398-3 2007 The sesquiterpene lactone parthenolide, an inhibition of NF-kappaB, has been used conventionally to treat migraines and inflammation. parthenolide 26-38 nuclear factor kappa B subunit 1 Homo sapiens 57-66 17259561-8 2006 Based on our promising studies selectively inhibiting EGFR (gefitinib), NFkappaB (parthenolide) or CD59 (neutralising antibody) together with antioestrogens, we propose that co-targeting strategies could markedly improve anti-tumour activity (notably enhancing cell kill) during the antihormone-responsive phase. parthenolide 82-94 nuclear factor kappa B subunit 1 Homo sapiens 72-80 16002075-4 2006 In addition, parthenolide, a nuclear factor kappaB (NF-kappaB) inhibitor, abolished VCAM-1 induction. parthenolide 13-25 nuclear factor kappa B subunit 1 Homo sapiens 52-61 16921510-1 2006 BACKGROUND: Nuclear Factor kappa B (NFkappaB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). parthenolide 201-213 nuclear factor kappa B subunit 1 Homo sapiens 12-34 16921510-1 2006 BACKGROUND: Nuclear Factor kappa B (NFkappaB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). parthenolide 201-213 nuclear factor kappa B subunit 1 Homo sapiens 36-44 16921510-4 2006 RESULTS: Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFkappaB-DNA binding. parthenolide 9-21 nuclear factor kappa B subunit 1 Homo sapiens 140-148 16921510-5 2006 Parthenolide downregulated anti-apoptotic genes under NFkappaB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 54-62 16878028-9 2006 To assess the NF-kappaB contribution to PIC-modulated inflammatory responses to septic shock, we treated with parthenolide, an NF-kappaB inhibitor before PIC and septic shock. parthenolide 110-122 nuclear factor kappa B subunit 1 Homo sapiens 127-136 16878028-11 2006 Inhibition of NF-kappaB by parthenolide did reduce IFN-alpha-mediated potentiation of the cytokine response and lethality from septic shock. parthenolide 27-39 nuclear factor kappa B subunit 1 Homo sapiens 14-23 16733051-12 2006 Perturbation of nuclear factor (NF)-kappaB signaling was strongly suggested by the fact that the wild-type Fhit expressants of SW480 cells tended to be sensitive to sulfasarazine or parthenolide, which are inhibitors of NF-kappaB. parthenolide 182-194 nuclear factor kappa B subunit 1 Homo sapiens 16-42 16873071-8 2006 Moreover, this research suggests that combined treatment approaches involving the use of tamoxifen in conjunction with agents that inhibit NFkappaB pathway signaling, such as parthenolide and genistein, warrant further study. parthenolide 175-187 nuclear factor kappa B subunit 1 Homo sapiens 139-147 16705314-2 2006 We have previously demonstrated that either Calphostin C (CC) (a protein kinase C (PKC) inhibitor) or Parthenolide (an NF-kappaB inhibitor) abrogates HDACI-induced transcriptional activation of NF-kappaB and p21, which is associated with profound potentiation of HDACI-mediated induction of apoptosis. parthenolide 102-114 nuclear factor kappa B subunit 1 Homo sapiens 119-128 16705314-2 2006 We have previously demonstrated that either Calphostin C (CC) (a protein kinase C (PKC) inhibitor) or Parthenolide (an NF-kappaB inhibitor) abrogates HDACI-induced transcriptional activation of NF-kappaB and p21, which is associated with profound potentiation of HDACI-mediated induction of apoptosis. parthenolide 102-114 nuclear factor kappa B subunit 1 Homo sapiens 194-203 16705314-9 2006 Kinase inhibitor-mediated suppression of NF-kappaB transcriptional activity played an important role in sensitising cancer cells to VA as direct inhibition of NF-kappaB by Parthenolide drastically synergised with VA to induce apoptosis (VA+Parthenolide: 60-90% compared to <20% following single-drug treatments). parthenolide 172-184 nuclear factor kappa B subunit 1 Homo sapiens 41-50 16705314-9 2006 Kinase inhibitor-mediated suppression of NF-kappaB transcriptional activity played an important role in sensitising cancer cells to VA as direct inhibition of NF-kappaB by Parthenolide drastically synergised with VA to induce apoptosis (VA+Parthenolide: 60-90% compared to <20% following single-drug treatments). parthenolide 172-184 nuclear factor kappa B subunit 1 Homo sapiens 159-168 16705314-9 2006 Kinase inhibitor-mediated suppression of NF-kappaB transcriptional activity played an important role in sensitising cancer cells to VA as direct inhibition of NF-kappaB by Parthenolide drastically synergised with VA to induce apoptosis (VA+Parthenolide: 60-90% compared to <20% following single-drug treatments). parthenolide 240-252 nuclear factor kappa B subunit 1 Homo sapiens 41-50 16705314-11 2006 The weak VA-mediated induction of apoptosis of thoracic cancer cells can be profoundly enhanced either by Parthenolide, a pharmacologic inhibitor of NF-kappaB, or by UCN-01 a kinase inhibitor that has already undergone phase I clinical development. parthenolide 106-118 nuclear factor kappa B subunit 1 Homo sapiens 149-158 16043032-6 2005 Parthenolide blocked NF-kappaB activation to a greater extent in EPA-treated cells and also decreased CP induced by NF-kappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 21-30 16043032-6 2005 Parthenolide blocked NF-kappaB activation to a greater extent in EPA-treated cells and also decreased CP induced by NF-kappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 116-125 15956258-7 2005 In addition, nuclear NF-kappaB levels were lower in residual tumors and lung metastasis of animals treated with parthenolide, docetaxel, or both. parthenolide 112-124 nuclear factor kappa B subunit 1 Homo sapiens 21-30 15956258-9 2005 These results for the first time reveal the significant in vivo chemosensitizing properties of parthenolide in the metastatic breast cancer setting and support the contention that metastases are very reliant on activation of NF-kappaB. parthenolide 95-107 nuclear factor kappa B subunit 1 Homo sapiens 225-234 15956258-1 2005 Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor kappaB (NF-kappaB) and activation of the c-Jun NH(2)-terminal kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 192-198 15827332-0 2005 Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 82-104 15956258-1 2005 Parthenolide, a sesquiterpene lactone, shows antitumor activity in vitro, which correlates with its ability to inhibit the DNA binding of the antiapoptotic transcription factor nuclear factor kappaB (NF-kappaB) and activation of the c-Jun NH(2)-terminal kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 200-209 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 52-60 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 180-192 nuclear factor kappa B subunit 1 Homo sapiens 104-112 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 194-196 nuclear factor kappa B subunit 1 Homo sapiens 52-60 15743683-3 2005 Oxidant (menadione 100 microMx30 min) activation of NFkappaB was prevented by pretreatment with various NFkappaB inhibitors, including the specific IkappaB kinase (IKK) inhibitor, parthenolide (PA), which was found to sensitize MCF-7/HER2 and BT474 but not MCF-7 cells to the antiestrogen tamoxifen. parthenolide 194-196 nuclear factor kappa B subunit 1 Homo sapiens 104-112 15827332-2 2005 We evaluated the effect of a novel NF-kappa B inhibitor, parthenolide, a sesquiterpene lactone isolated from the herb feverfew, in three human pancreatic tumor cell lines (BxPC-3, PANC-1, and MIA PaCa-2). parthenolide 57-69 nuclear factor kappa B subunit 1 Homo sapiens 35-45 15827332-4 2005 Parthenolide treatment also dose-dependently increased the amount of the NF-kappa B inhibitory protein, I kappa B-alpha, and decreased NF-kappa B DNA binding activity. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 73-83 15827332-4 2005 Parthenolide treatment also dose-dependently increased the amount of the NF-kappa B inhibitory protein, I kappa B-alpha, and decreased NF-kappa B DNA binding activity. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 135-145 15467918-9 2004 Parthenolide, an IkappaB kinase inhibitor, prevented up-regulation of MCP-1 by fibrinogen, linking this response to NF-kappaB activation. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 116-125 15657351-2 2005 The purpose of this study was to elucidate the mechanism by which NFkappaB up-regulation contributes to Faslodex resistance and to determine whether pharmacologic inhibition of NFkappaB by the small molecule parthenolide could restore Faslodex-mediated suppression of cell growth. parthenolide 208-220 nuclear factor kappa B subunit 1 Homo sapiens 66-74 15657351-2 2005 The purpose of this study was to elucidate the mechanism by which NFkappaB up-regulation contributes to Faslodex resistance and to determine whether pharmacologic inhibition of NFkappaB by the small molecule parthenolide could restore Faslodex-mediated suppression of cell growth. parthenolide 208-220 nuclear factor kappa B subunit 1 Homo sapiens 177-185 15256485-0 2004 Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. parthenolide 92-104 nuclear factor kappa B subunit 1 Homo sapiens 11-20 12851492-0 2003 Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-kappaB parthenolide. parthenolide 129-141 nuclear factor kappa B subunit 1 Homo sapiens 119-128 15328189-3 2004 The functional relevance of NF-kappaB DNA binding was assessed by both cDNA array analyses and proliferation assays of prostate cancer cells with and without exposure to an NF-kappaB inhibitor, parthenolide. parthenolide 194-206 nuclear factor kappa B subunit 1 Homo sapiens 28-37 15328189-3 2004 The functional relevance of NF-kappaB DNA binding was assessed by both cDNA array analyses and proliferation assays of prostate cancer cells with and without exposure to an NF-kappaB inhibitor, parthenolide. parthenolide 194-206 nuclear factor kappa B subunit 1 Homo sapiens 173-182 15328189-7 2004 The binding was inhibited by parthenolide, and this agent also decreased multiple gene transcripts under the control of NF-kappaB and inhibited proliferation of prostate cancer cells. parthenolide 29-41 nuclear factor kappa B subunit 1 Homo sapiens 120-129 15183076-0 2004 Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. parthenolide 90-102 nuclear factor kappa B subunit 1 Homo sapiens 33-42 15015572-5 2004 A series of assays were also performed in which we utilized parthenolide, a specific inhibitor of NF-kappaB, to analyze the possible role that the NF-kappaB/IkappaB signaling pathway has in mediating paclitaxel-induced apoptosis. parthenolide 60-72 nuclear factor kappa B subunit 1 Homo sapiens 98-107 15015572-8 2004 Parthenolide was found to inhibit paclitaxel-induced activation of the NF-kappaB/IkappaB signal pathway as well as apoptotic cell death. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 71-80 12570770-8 2003 Our ethnopharmacological research led to the identification of sesquiterpene lactones (SLs) like parthenolide as potent and relatively specific inhibitors of the transcription factor NF-kappaB, an important mediator of the inflammatory process. parthenolide 97-109 nuclear factor kappa B subunit 1 Homo sapiens 183-192 11588049-9 2001 Treatment of cells with a specific NFkappaB inhibitor, parthenolide, led to loss of NFkappaB activity and down-regulation of antiapoptotic c-IAP2. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 35-43 11877332-0 2002 Enhancement of 1 alpha,25-dihydroxyvitamin D(3)-induced differentiation of human leukaemia HL-60 cells into monocytes by parthenolide via inhibition of NF-kappa B activity. parthenolide 121-133 nuclear factor kappa B subunit 1 Homo sapiens 152-162 11877332-3 2002 In this report parthenolide (PT), a sesquiterpene lactone of herbal remedies such as feverfew (Tanacetum parthenium) with NF-kappa B inhibitory activity, markedly increased the degree of human leukaemia HL-60 cell differentiation when simultaneously combined with 5 nM 1 alpha,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)). parthenolide 15-27 nuclear factor kappa B subunit 1 Homo sapiens 122-132 11877332-3 2002 In this report parthenolide (PT), a sesquiterpene lactone of herbal remedies such as feverfew (Tanacetum parthenium) with NF-kappa B inhibitory activity, markedly increased the degree of human leukaemia HL-60 cell differentiation when simultaneously combined with 5 nM 1 alpha,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)). parthenolide 29-31 nuclear factor kappa B subunit 1 Homo sapiens 122-132 12067985-8 2002 Parthenolide, a potent and specific inhibitor of NFkappaB, inhibits the anchorage-dependent proliferation of antiestrogen-resistant but not antiestrogen-responsive cells. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 49-57 11921057-8 2002 IkappaBalpha degradation, NF-kappaB activation, and iNOS expression were attenuated by parthenolide (3mg/kg), the active constituent of feverfew, an anti-inflammatory drug used for migraine treatment. parthenolide 87-99 nuclear factor kappa B subunit 1 Homo sapiens 26-35 11598079-9 2001 In the complete absence of activated NF-kappaB, when Mono Mac 6 cells were pretreated with the more potent NF-kappaB inhibitors MG-132 and parthenolide a C. pneumoniae-mediated rescue of cells from induced apoptosis could not be achieved. parthenolide 139-151 nuclear factor kappa B subunit 1 Homo sapiens 107-116 11588049-9 2001 Treatment of cells with a specific NFkappaB inhibitor, parthenolide, led to loss of NFkappaB activity and down-regulation of antiapoptotic c-IAP2. parthenolide 55-67 nuclear factor kappa B subunit 1 Homo sapiens 84-92 10704251-3 2000 Because activation of NF-kappaB is involved in the regulation of the chemokine interleukin 8 (IL-8), we hypothesized that the sesquiterpene lactones, isohelenin and parthenolide, would inhibit IL-8 gene expression in cultured human respiratory epithelium. parthenolide 165-177 nuclear factor kappa B subunit 1 Homo sapiens 22-31 11428868-6 2001 This induction was completely blocked by simultaneous administration of the two drugs or by incubation with inhibitors for activation of NF-kappaB such as BAY11-7085, CAPE, and parthenolide. parthenolide 177-189 nuclear factor kappa B subunit 1 Homo sapiens 137-146 11360202-6 2001 We also show that parthenolide, a NF-kappaB inhibitor, sensitizes breast cancer cells to tunicamycin. parthenolide 18-30 nuclear factor kappa B subunit 1 Homo sapiens 34-43 11500489-9 2001 In addition, we provide evidence that parthenolide uses a similar mechanism to other SLs in inhibiting NF-kappaB. parthenolide 38-50 nuclear factor kappa B subunit 1 Homo sapiens 103-112 11500489-10 2001 Contrary to previous reports, we show that parthenolide, like other SLs, inhibits NF-kappaB most probably by alkylating p65 at Cys(38). parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 82-91 10704251-7 2000 In addition, pretreatment with isohelenin or parthenolide inhibited TNF-alpha-mediated degradation of the NF-kappaB inhibitory protein, I-kappaBalpha. parthenolide 45-57 nuclear factor kappa B subunit 1 Homo sapiens 106-115 10553091-0 1999 The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. parthenolide 43-55 nuclear factor kappa B subunit 1 Homo sapiens 65-75 10553091-3 1999 This study shows that the sesquiterpene lactone parthenolide inhibits a common step in NF-kappa B activation by preventing the TNF-alpha-induced induction of I kappa B kinase (IKK) and IKK beta, without affecting the activation of p38 and c-Jun N-terminal kinase. parthenolide 48-60 nuclear factor kappa B subunit 1 Homo sapiens 87-97 10553091-4 1999 Parthenolide impairs NF-kappa B-dependent transcription triggered by expression of TNFR-associated factor-2, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEKK1), and NF-kappa B-inducing kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 21-31 10553091-4 1999 Parthenolide impairs NF-kappa B-dependent transcription triggered by expression of TNFR-associated factor-2, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEKK1), and NF-kappa B-inducing kinase. parthenolide 0-12 nuclear factor kappa B subunit 1 Homo sapiens 200-210